Volume 11, Issue 8, Pages (August 2010)

Slides:



Advertisements
Similar presentations
Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)
Advertisements

Volume 14, Issue 12, Pages (November 2013)
Volume 385, Issue 9980, Pages (May 2015)
Volume 12, Issue 9, Pages (September 2011)
Volume 16, Issue 2, Pages (February 2015)
Volume 12, Issue 11, Pages (October 2011)
Volume 376, Issue 9747, Pages (October 2010)
Volume 15, Issue 6, Pages (May 2014)
The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis  K.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Volume 148, Issue 1, Pages e2 (January 2015)
Volume 377, Issue 9783, Pages (June 2011)
Volume 13, Issue 12, Pages (December 2012)
Volume 389, Issue 10076, Pages (April 2017)
Volume 148, Issue 1, Pages (January 2015)
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study  Matthew Waxman, MD,
Volume 10, Issue 6, Pages (June 2009)
Volume 15, Issue 4, Pages (April 2014)
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Volume 14, Issue 7, Pages (June 2013)
Volume 12, Issue 12, Pages (November 2011)
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
Volume 14, Issue 8, Pages (July 2013)
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.
Volume 14, Issue 8, Pages (July 2013)
Volume 12, Issue 7, Pages (July 2011)
Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group  Shadia Jalal,
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.
Volume 13, Issue 12, Pages (December 2012)
Volume 11, Issue 4, Pages (April 2010)
Volume 14, Issue 11, Pages (October 2013)
Volume 18, Issue 3, Pages (March 2017)
Volume 385, Issue 9962, Pages (January 2015)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study  Enric Domingo,
Volume 19, Issue 4, Pages (April 2018)
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.
Volume 20, Issue 1, Pages (January 2019)
Volume 18, Issue 8, Pages (August 2017)
Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.
Volume 15, Issue 6, Pages (May 2014)
Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A
Volume 5, Issue 4, Pages (April 2018)
Volume 16, Issue 8, Pages (August 2015)
Volume 14, Issue 8, Pages (July 2013)
Volume 373, Issue 9658, Pages (January 2009)
Volume 15, Issue 6, Pages (May 2014)
EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer  Philip C. Mack,
Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study  Marcello Carlo Ambrogi,
Volume 376, Issue 9747, Pages (October 2010)
Volume 14, Issue 9, Pages (August 2013)
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.
PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients  Hideki Endoh, MD, PhD,
Pulmonary Resection for Metastases from Colorectal Cancer
Is Pneumonectomy After Induction Chemotherapy for Non-small Cell Lung Cancer a Reasonable Procedure? A Multicenter Retrospective Study of 228 Cases  Yoann.
KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value 
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed  D.
Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors  Sean M. Parker, BS, R. Alfredo Siochi,
Volume 14, Issue 7, Pages (June 2013)
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer:
Volume 371, Issue 9617, Pages (March 2008)
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.
Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer  Gerold Bepler,
A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.
Volume 20, Issue 8, Pages (August 2019)
Presentation transcript:

Volume 11, Issue 8, Pages 753-762 (August 2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis  Wendy De Roock, MD, Bart Claes, MSc, David Bernasconi, MSc, Jef De Schutter, MSc, Bart Biesmans, MSc, Prof George Fountzilas, MD, Konstantine T Kalogeras, MD, Vassiliki Kotoula, MD, Demetris Papamichael, FRCP, Prof Pierre Laurent-Puig, MD, Prof Frédérique Penault-Llorca, MD, Prof Philippe Rougier, MD, Bruno Vincenzi, MD, Daniele Santini, MD, Prof Giuseppe Tonini, MD, Federico Cappuzzo, MD, Milo Frattini, PhD, Francesca Molinari, PhD, Piercarlo Saletti, MD, Sara De Dosso, MD, Miriam Martini, PhD, Prof Alberto Bardelli, PhD, Prof Salvatore Siena, MD, Andrea Sartore-Bianchi, MD, Prof Josep Tabernero, MD, Teresa Macarulla, MD, Frédéric Di Fiore, MD, Alice Oden Gangloff, MD, Prof Fortunato Ciardiello, MD, Prof Per Pfeiffer, MD, Camilla Qvortrup, MD, Tine Plato Hansen, MD, Prof Eric Van Cutsem, MD, Prof Hubert Piessevaux, MD, Prof Diether Lambrechts, PhD, Mauro Delorenzi, PhD, Prof Sabine Tejpar, MD  The Lancet Oncology  Volume 11, Issue 8, Pages 753-762 (August 2010) DOI: 10.1016/S1470-2045(10)70130-3 Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 1 Associations between mutations Absolute numbers of KRAS wild type, KRAS mutant, BRAF mutant, NRAS mutant, PIK3CA exon 9 mutant samples (A), and PIK3CA exon 20 mutant (B) samples are shown. The Lancet Oncology 2010 11, 753-762DOI: (10.1016/S1470-2045(10)70130-3) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 2 Conditional inference trees for objective response (A), disease control (B), progression-free survival (C), and overall survival (D) p values correspond to permutation test.11 (A) The fraction of objective responders in each terminal node is indicated by the height of the blue bar. The tree shows that to best predict response to cetuximab, KRAS mutations should be assessed first (36·3% response rate), BRAF second (38·4% response rate), NRAS third (39·9% response rate), and PIK3CA exon 20 fourth (41·2% response rate). PIK3CA exon 9 mutation state is not retained in the model. (B) The tree shows that to best predict disease control, KRAS mutations should be assessed first (76·7% disease control), BRAF second (79·3% disease control), PIK3CA exon 20 third (80·6% disease control), and NRAS fourth (82·0% disease control). PIK3CA exon 9 mutation state is not retained in the model. (C) Kaplan-Meier estimates of the progression-free survival time (in weeks) are shown in the terminal nodes. The tree shows that to best predict progression-free survival (PFS), KRAS mutations should be assessed first (median PFS 24 weeks; range 24–29), BRAF second (median PFS 28 weeks; range 24–30), PIK3CA exon 20 third (median PFS 28 weeks; range 24–31), and NRAS fourth (median PFS 29 weeks; 24–32). PIK3CA exon 9 mutation state is not retained in the model. (D) Kaplan-Meier estimates of the overall survival time (in weeks) are shown in the terminal nodes. The tree shows that to best predict overall survival, KRAS mutations should be assessed first (median overall survival 49 weeks; range 46–55), BRAF second (median overall survival 52 weeks; range 47–58), and PIK3CA exon 20 third (median overall survival 54 weeks; range 48–59). NRAS and PIK3CA exon 9 mutation state are not retained in the model. PIK×20=PIK3CA exon 20. >0=mutant state. ≤0=wild-type state. The Lancet Oncology 2010 11, 753-762DOI: (10.1016/S1470-2045(10)70130-3) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 3 The improvement in response prediction gained by assessing the mutation status of each gene Patients with missing data for any of the markers studied in this analysis were omitted from the start. The green bars represent responders; the orange bars non-responders. Bottom bars represent mutant tumours; upper bars wild-type tumours. The size of the bars is in agreement with the corresponding percentages. PIK×20=PIK3CA exon 20. The Lancet Oncology 2010 11, 753-762DOI: (10.1016/S1470-2045(10)70130-3) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 4 Receiver-operating characteristic curve for objective response PIK×9=PIK3CA exon 9. PIK×20=PIK3CA exon 20. The Lancet Oncology 2010 11, 753-762DOI: (10.1016/S1470-2045(10)70130-3) Copyright © 2010 Elsevier Ltd Terms and Conditions